

**Minutes of the September 4, 2015  
Pharmacy & Therapeutics (P&T) Committee Meeting  
South Dakota Department of Social Services, Division of Medical Services**

**Members present**

Bill Ladwig, RPh; Michelle Baack; Mikel Holland; Richard Holm; Dana Darger; James Engelbrecht

**DSS staff present**

Mike Jockheck, RPh

**Administrative business**

The P&T meeting was called to order by M. Baack at 1:00 p.m. The minutes of the June 5, 2015 meeting were presented. B. Ladwig made a motion to approve. R. Holm seconded the motion. The motion was approved unanimously.

**Review of Orkambi**

A motion was made by M. Baack to move Orkambi to the first of the agenda for discussion. R. Holm seconded the motion. The motion was approved unanimously. The committee reviewed Orkambi clinical information. James Wallace, practicing physician, spoke on behalf of Orkambi. A motion was made by J. Engelbrecht to place Orkambi on prior authorization with criteria including specialist involved in therapy and genotyping. R. Holm seconded the motion. The motion was approved unanimously.

**Prior authorization update and statistics**

The committee reviewed the prior authorization (PA) activity for July 2015. There were a total of 3,052 PAs processed in the month of July, with 99.90% of those requests responded to in less than eight hours. There were 2,377 requests (78%) received electronically and 675 requests (22%) received by fax.

**Analysis of the top 15 therapeutic classes**

The committee reviewed the top 15 therapeutic classes by total cost of claims from 04/1/2015 – 06/30/2015. The top five classes were antipsychotics, respiratory and CNS stimulants, amphetamines, insulins, and central nervous system agents, misc. The top 15 therapeutic classes make up 37.94% of total claims. The committee also reviewed the top 50 drugs based on total claims cost and number of claims. The top 50 drugs by claims cost make up 20.41% of total claims. The committee asked for a review of antipsychotic data, Lyrica data, Enbrel/Humira data, and a trend of hydrocodone/APAP data for the December meeting.

**Akynzeo second review**

The committee reviewed the prior authorization form provided for Akynzeo. There was no public comment. B. Ladwig made a motion to approve the form. J. Engelbrecht seconded the motion. The motion was approved unanimously.

**Nuessa second review**

The committee reviewed the prior authorization form provided for Nuessa. There was no public comment. J. Engelbrecht made a motion to approve the Nuessa form. R. Holm seconded the motion. The motion was approved unanimously.

**Medications used to treat irritable bowel syndrome (IBS) review**

The committee reviewed clinical information for medications used to treat IBS. Taylor Bradshaw, representing Allergan, addressed the committee. The committee requested that a form be developed and brought back to the December meeting.

**SGLT2 review**

The committee reviewed SGLT2 clinical information. There was no public comment. The committee tabled this topic.

**DPP-4 review**

The committee reviewed DPP-4 clinical information. There was no public comment. The committee tabled this topic.

**Glyxambi review**

The committee reviewed Glyxambi clinical information. M. Dunze, representing Boehringer Ingelheim, addressed the committee. The committee tabled this topic.

**Entresto review**

The committee reviewed Entresto clinical information. Kori Hack, representing Novartis, addressed the committee. The committee tabled this topic.

**Corlanor review**

The committee reviewed Corlanor clinical information. Amanda Champ, representing Amgen, addressed the committee. The committee tabled this topic.

**PCSK9 review**

The committee reviewed PCSK9 inhibitors clinical information. Amanda Champ, representing Amgen, addressed the committee. The committee requested that a form be developed and brought back to the December meeting.

The next meeting is scheduled for December 4, 2015. B. Ladwig made a motion to adjourn the P&T Committee meeting. R. Holm seconded the motion. The motion passed unanimously and the meeting was adjourned.